Volume | 81,315 |
|
|||||
News | - | ||||||
Day High | 96.59 | Low High |
|||||
Day Low | 94.19 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
ICU Medical Inc | ICUI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
94.19 | 94.19 | 96.59 | 94.84 | 94.53 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
4,426 | 81,315 | US$ 95.49 | US$ 7,764,879 | - | 78.28 - 212.43 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:01:11 | 16 | US$ 94.84 | USD |
ICU Medical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.29B | 24.14M | - | 2.28B | -29.66M | -1.23 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ICU Medical News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ICUI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 97.13 | 99.5301 | 93.355 | 96.25 | 158,780 | -2.29 | -2.36% |
1 Month | 107.72 | 108.43 | 93.355 | 100.10 | 203,714 | -12.88 | -11.96% |
3 Months | 91.49 | 123.46 | 86.80 | 101.70 | 252,727 | 3.35 | 3.66% |
6 Months | 103.71 | 123.46 | 78.28 | 94.72 | 328,213 | -8.87 | -8.55% |
1 Year | 180.12 | 212.43 | 78.28 | 117.90 | 257,501 | -85.28 | -47.35% |
3 Years | 211.62 | 282.00 | 78.28 | 162.19 | 205,113 | -116.78 | -55.18% |
5 Years | 226.27 | 282.00 | 78.28 | 173.40 | 188,683 | -131.43 | -58.09% |
ICU Medical Description
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. After ICU's acquisition of Hospira Infusion Systems from Pfizer in 2017, it became one of the largest players in this concentrated industry, holding top-tier positions in its major reporting segments: infusion consumables (37% of 2020 revenue), IV solutions (31%), infusion systems (28%), and critical care (4%). The combined entity remains primarily U.S. focused, generating over 70% of its sales domestically. |